Some of our cancer centers are experiencing issues.  View More Important Notifications x
texas oncology more breakthroughs. more victories

Share:

 
 

Horizon Circle Research & Clinical Trials

Texas Oncology-Horizon Circle participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Horizon Circle (Expand)

Biliary Cancer

STAR Infigratinib vs Gem/Cis Cholangio

A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301) Read More

Phase: III

Bladder Cancer

STAR PH 2 ASG-22CE Urothelial Cancer

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002) Read More

Phase: I/II

Biomarker Advcd Uro Cncer and FGFR Aber

Biomarker Study to Identify Subjects with Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002) Read More

Phase: IV

Breast Cancer

FLEX Registry: Evaluate New Gene Express

MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read More

STAR Ph 3 Tuca/Placbo + T-DM1 HER2+

STAR: Randomized double-blind phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016) Read More

Phase: III

Cervical Cancer

STAR Ph2 Ak104 Cervical Cancer

A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU) Read More

Phase: II

Colon Cancer

STAR: PH2 Tuca+ Tras HER2+ CC

MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017) Read More

Phase: II

Esophageal Cancer

STAR Ph3 Sinti vs Placebo ESCC

A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301 Read More

Phase: III

Essential Thrombocythemia

STAR PH3 Pacritinib vs MD choice in MF

A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203) Read More

Phase: III

Gall Bladder Cancer

STAR Infigratinib vs Gem/Cis Cholangio

A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301) Read More

Phase: III

Head and Neck Cancer

Ph3 GC4419 Oral Mucositis H&N

ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced Non-Metastatic Head and Neck Cancer (GTI-4419-301) Read More

Phase: III

Lung Cancer

STAR Ph1/2 BLU667 thy NSCLC Sol tum

A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Read More

Phase: I/II

STAR-PH3 pral(Blu-667) RET-fusion mNSCLC

A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303) Read More

Phase: III

STAR Ph3 ALK+ mNSCLC (Brigatinib-3001)

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®) Read More

Phase: III

STAR KEAP1/NRF2 NSCLC

CX-839-014 ""KEAPSAKE"": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Read More

Phase: II"

Lymphomas

STAR BV in older pts w/1L cHL or PTCL

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy Read More

Phase: II

Myelofibrosis

STAR PH3 Pacritinib vs MD choice in MF

A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203) Read More

Phase: III

Non-Small Cell Lung Cancer

LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure

Phase: III

Prostate Cancer

STAR Ph3 Nirap+Abirat+Pred mCRPC

A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001) Read More

Phase: III

A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer (COMPPARE)

Biomarker DNA Defect Men Prostate

Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002) Read More

STAR Abirat+pred +/- abemaciclib mCRPC

CYCLONE 2: A Phase 2 Randomized Double-blind Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM) Read More

Phase: II

STAR Rucaparib v PhysC mCRPC (TRITON3)

TRITON3: A Multicenter Randomized Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063) Read More

Phase: III

Rectal Cancer

STAR: PH2 Tuca+ Tras HER2+ CC

MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017) Read More

Phase: II

Skin Cancer

STAR Ph1 CX-4945 Basal Cell Carcinoma

A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07) Read More

Phase: I

Solid Tumors

STAR Ph2 Pemigatinib Solids FGFR

(INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Read More

Phase: II

STAR Ph1/2 BLU667 thy NSCLC Sol tum

A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Read More

Phase: I/II

STAR Ph2 Erdafitinib FGFR Solid Tumors

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002) Read More

Phase: II

Thyroid Cancer

STAR Ph1/2 BLU667 thy NSCLC Sol tum

A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Read More

Phase: I/II

Urothelial Cancer

STAR Ph3 FGFR erdafitinib urothelial

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) Read More

Phase: III

STAR PH 2 ASG-22CE Urothelial Cancer

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002) Read More

Phase: I/II

Biomarker Advcd Uro Cncer and FGFR Aber

Biomarker Study to Identify Subjects with Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002) Read More

Phase: IV